MERIX

March 8, 2004

Mr. George F. Bailey,
Compliance Officer
Department of Health & Human Services
Food and Drug Administration
550 West Jackson Blvd., 15th Floor
Chicago, IL 60661

RE: Response to Warning Letter 5/2003 Ref. CHI-14-03 VIA: CDROM and Federal Express

Dear Mr. Bailey,

This letter is sent in further response to the letter captioned above and is in addition to our Warning Letter Response dated March 8, 2004 and more specifically details the actions taken by Merix to correct observations cited.

As previously noted, the letter in reference pertained to outdated materials and labeling that had in fact been changed more than a year prior to receipt of said letter. As a matter of record, also please note that Merix requested a deadline extension to respond to the Warning Letter.

Since receipt of said letter Merix has:

- Edited their website and removed the statements cited in the Warning Letter and has moved research information and letters from doctors and customers from that website to a different domain.
- Changed all packaging and labeling.
- Submitted labeling to the FDA
- Removed the words "anti-viral from all packaging
- Removed any potentially misleading medical claims as cited.

As previously stated in our initial response and at our meeting, we strive to meet full compliance requirements of the FDA and believe this represents a clear portrayal of our intent to comply with regulations. We appreciate your assistance as we move forward. Please contact me if you have any questions.

Attached herewith is an electronic copy of our responses to the warning letter issued to Meryl J. Squires, President of Merix Pharmaceutical Corp. on May 20th 2003. We request that both responses be posted on your website with the warning letter in accordance with the guidelines of your response letter pilot program.

Thank you very much for offering this valuable service.

Sincerely,

Meryl J. Squires
President